Hennion & Walsh Asset Management Inc. Acquires 993 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Hennion & Walsh Asset Management Inc. raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 18.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,342 shares of the medical instruments supplier’s stock after buying an additional 993 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in LeMaitre Vascular were worth $421,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. SRS Capital Advisors Inc. lifted its position in LeMaitre Vascular by 325.5% in the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 524 shares in the last quarter. Personal CFO Solutions LLC raised its stake in shares of LeMaitre Vascular by 6.4% in the fourth quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock worth $316,000 after purchasing an additional 336 shares during the last quarter. KLR Investment Advisors LLC bought a new position in shares of LeMaitre Vascular in the fourth quarter valued at approximately $351,000. Riverwater Partners LLC boosted its position in shares of LeMaitre Vascular by 2.5% during the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after buying an additional 198 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in shares of LeMaitre Vascular by 14.2% during the third quarter. Deutsche Bank AG now owns 10,014 shares of the medical instruments supplier’s stock valued at $546,000 after buying an additional 1,246 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $81.30 on Thursday. LeMaitre Vascular, Inc. has a 1 year low of $44.27 and a 1 year high of $84.15. The business has a fifty day simple moving average of $77.49 and a two-hundred day simple moving average of $67.18. The company has a market capitalization of $1.82 billion, a P/E ratio of 53.84, a P/E/G ratio of 2.51 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. The business had revenue of $53.48 million for the quarter, compared to analysts’ expectations of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.27 EPS. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 30th. Investors of record on Thursday, May 16th were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend was Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Roth Capital upgraded LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. JMP Securities boosted their price target on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a report on Friday, May 3rd. Stifel Nicolaus upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and increased their price objective for the company from $59.00 to $75.00 in a research note on Friday, April 26th. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, June 22nd. Finally, Barrington Research upped their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $77.57.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 5,025 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.62, for a total transaction of $379,990.50. Following the sale, the director now owns 14,114 shares in the company, valued at $1,067,300.68. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other LeMaitre Vascular news, Director Bridget A. Ross sold 5,500 shares of LeMaitre Vascular stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $77.99, for a total transaction of $428,945.00. Following the completion of the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $177,661.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David B. Roberts sold 5,025 shares of the stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $75.62, for a total transaction of $379,990.50. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at $1,067,300.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 87,431 shares of company stock worth $6,627,520. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.